| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $761.4M | +12.8% |
| Cost of Revenue | $13.0M | +19.3% |
| R&D Expense | $254.9M | +3.2% |
| SG&A Expense | $448.7M | +60.1% |
| Operating Income | $44.8M | -67.3% |
| Pre-tax Income | $66.5M | -58.8% |
| Income Tax | -$33.2M | -263.6% |
| Net Income | $99.7M | -29.4% |
| EPS (Basic) | $0.95 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $120.5M | -5.6% |
| Short-term Investments | $251.7M | -1.6% |
| Accounts Receivable | $59.8M | +10.8% |
| Inventory | $12.9M | +3.7% |
| Current Assets | $485.5M | +2.9% |
| Total Assets | $836.7M | -0.5% |
| Current Liabilities | $166.1M | +18.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $142.0M | -28.3% |
| Capital Expenditures | $211K | -90.3% |
| Investing Cash Flow | $69.8M | +139.3% |
| Financing Cash Flow | -$220.4M | -677.3% |
| Free Cash Flow | $141.8M | -27.6% |
| -29.6% |
| EPS (Diluted) | $0.82 | -33.3% |
| Total Liabilities |
| $188.8M |
| +17.3% |
| Stockholders' Equity | $647.8M | -4.7% |